FDA approves first oral GLP-1 treatment for type 2 diabetes | FDA

FDA approves first oral GLP-1 treatment for type 2 diabetes | FDA

FDA approves first oral GLP-1 treatment for type 2 diabetes

The U.S. Food and Drug Administration approves Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.

• Read Announcement